Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...

Researchers found those on 50mg of amycretin lost 10.4% of their body weight, while those taking two doses of 50mg – the maximum tested – lost 13.1%. This is compared to an average loss of 1.1 ...

Novo Nordisk reported that, after 12 weeks of treatment, the once-daily doses of 50 mg and two times 50 mg of oral amycretin achieved weight loss of 10.4% and 13.1%, respectively, versus a 1.2% ...

Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, which target GLP-1 and GIPR receptors. Following the release of the trial results, ...

A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which targets both GLP-1 and amylin receptors to help control blood sugar and ...

Amycretin mimics the action of two different hunger-related hormones at once, says Novo Nordisk, the Danish pharma company developing the drug. The drug mimics glucagon, which is the hormone also ...

Amycretin, a new weight loss drug developed by Novo Nordisk, helped participants lose up to 24.3% of body weight in just 36 weeks—outperforming popular jabs like Wegovy and Mounjaro.

Subcutaneous amycretin phase 1 b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American ...

PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to ...